Results 111 to 120 of about 121,877 (300)

Imaging of Neuroendocrine Prostatic Carcinoma. [PDF]

Cancers (Basel), 2021
Taher A, Jensen CT, Yedururi S, Surasi DS, Faria SC, Bathala TK, Mujtaba B, Bhosale P, Wagner-Bartak N, Morani AC.   +9 more
europepmc   +1 more source

Screening for prostatic cancer: the case for. [PDF]

, 1993
Allhoff, E. P., Kuczyk, M., Liedke, S. G., Stief, Christian Georg   +3 more
core   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, EarlyView.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

Dural metastases from prostatic cancer or chronic subdural hematoma

Revista Ciencias Biomédicas, 2012
Introduction: dural metastases of prostatic adenocarcinoma appear in advanced stagesof the disease and they can be the first manifestation of a prostatic carcinoma, evenwithout urological symptoms.Clinical case: a 71 year-old patient without previous ...
Taboada-Lora Luis Roberto, Bernal-Bernal David Alejandro, Navarro-Tovar Saúl   +2 more
doaj  

⁶⁸Ga-PSMA PET-CT and PSMA score affecting therapeutic decision-making in high-risk prostatic carcinoma. [PDF]

Pol J Radiol, 2023
Yasmin T, Younis MN, Ameer K, Farooq A, Shahid A.   +4 more
europepmc   +1 more source

Gene amplifications associated with the development of hormone- resistant prostate cancer [PDF]

, 2003
Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential.
Bartlett, J.M.S., Edwards, J., Krishnan, S., Witton, C.J.   +3 more
core  

Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy

Advanced Science, EarlyView.
Biomimetic MOF‐based drug delivery nanoplatforms synthesized using liposomes or cell membranes as camouflage for multiple cancer therapeutics. ABSTRACT The integration of metal‐organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine.
Qilu Wu, Jia Song Deon Chon, Yuxiao Feng, Kang Liang, Shiming Li, Can Yang Zhang, Jun Ge   +6 more
wiley   +1 more source

Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. [PDF]

Histopathology, 2022
Gopalan A, Al-Ahmadie H, Chen YB, Sarungbam J, Sirintrapun SJ, Tickoo SK, Reuter VE, Fine SW.   +7 more
europepmc   +1 more source

Urinary cholesterol in follow-up of patients with urologic carcinomas or benign prostatic hyperplasia [PDF]

, 1981
Jüngst, Dieter, Karl, Hans Josef, Lazik, E., Tauber, R.   +3 more
core   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source